Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical and Laboratory Evaluation of Acute Rejection, Myocyte Growth, Repair, and Oxidative Stress Following de Novo Cardiac Transplant: A Comparison Between Tacrolimus- and Cyclosporine - Based Immunoprophylactic Regimens With MPA TDM.

Trial Profile

Clinical and Laboratory Evaluation of Acute Rejection, Myocyte Growth, Repair, and Oxidative Stress Following de Novo Cardiac Transplant: A Comparison Between Tacrolimus- and Cyclosporine - Based Immunoprophylactic Regimens With MPA TDM.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jun 2017

At a glance

  • Drugs Ciclosporin; Methylprednisolone; Mycophenolate mofetil; Mycophenolate mofetil; Prednisone; Tacrolimus
  • Indications Heart transplant rejection
  • Focus Biomarker; Therapeutic Use
  • Sponsors Astellas Pharma; Astellas Pharma Canada
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 12 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Jul 2008 The expected completion date for this trial has changed from May 2008 to Jul 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top